Further, mutated STAG2 is defined as a prognostic marker of high-risk (if not co-occurring with favorable risk AML subtypes) incentivizing intensive treatment and, potentially, allogeneic hematopoietic stem cell transplantation (HCT) [3]. Here, STAG2 is linked to acute myeloid leukemia.